GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Cyclically Adjusted Price-to-FCF

Diamyd Medical AB (OSTO:DMYD B) Cyclically Adjusted Price-to-FCF : (As of Jun. 30, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Diamyd Medical AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Diamyd Medical AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Cyclically Adjusted Price-to-FCF Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Diamyd Medical AB Quarterly Data
Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Diamyd Medical AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Diamyd Medical AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

Diamyd Medical AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Diamyd Medical AB's Cyclically Adjusted FCF per Share for the quarter that ended in May. 2025 is calculated as:

For example, Diamyd Medical AB's adjusted Free Cash Flow per Share data for the three months ended in May. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of May. 2025 (Change)*Current CPI (May. 2025)
=-0.455/132.8245*132.8245
=-0.455

Current CPI (May. 2025) = 132.8245.

Diamyd Medical AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201508 -0.129 99.829 -0.172
201511 -0.168 100.129 -0.223
201602 -0.170 100.253 -0.225
201605 -0.142 100.914 -0.187
201608 -0.118 100.968 -0.155
201611 -0.153 101.517 -0.200
201702 -0.170 102.037 -0.221
201705 -0.179 102.679 -0.232
201708 -0.189 103.138 -0.243
201711 -0.209 103.413 -0.268
201802 -0.189 103.678 -0.242
201805 -0.169 104.632 -0.215
201808 -0.155 105.197 -0.196
201811 -0.186 105.443 -0.234
201902 -0.127 105.641 -0.160
201905 -0.132 106.895 -0.164
201908 -0.799 106.716 -0.994
201911 -0.086 107.345 -0.106
202002 0.523 106.742 0.651
202005 -0.095 106.882 -0.118
202008 -0.101 107.571 -0.125
202011 -0.224 107.549 -0.277
202102 -0.216 108.190 -0.265
202105 -0.377 108.838 -0.460
202108 -0.754 109.780 -0.912
202111 -0.573 111.069 -0.685
202202 -0.278 112.834 -0.327
202205 -0.456 116.746 -0.519
202208 -0.395 120.573 -0.435
202211 -0.368 123.803 -0.395
202302 -0.378 126.321 -0.397
202305 -0.351 128.034 -0.364
202308 -0.446 129.560 -0.457
202311 -0.354 130.958 -0.359
202402 -0.410 132.046 -0.412
202405 -0.387 132.818 -0.387
202408 -0.293 132.052 -0.295
202411 -0.434 133.000 -0.433
202502 -0.470 133.744 -0.467
202505 -0.455 132.825 -0.455

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Diamyd Medical AB  (OSTO:DMYD B) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Diamyd Medical AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Industry
Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines